Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 15.184
Filter
1.
Nitric Oxide ; 150: 47-52, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-39097183

ABSTRACT

In the vasculature, nitric oxide (NO) is produced in the endothelium by endothelial nitric oxide synthase (eNOS) and is critical for the regulation of blood flow and blood pressure. Blood flow may also be regulated by the formation of nitrite-derived NO catalyzed by hemoproteins under hypoxic conditions. We sought to investigate whether nitrite administration may affect tissue perfusion and systemic hemodynamics in WT and eNOS knockout mice. We found that global eNOS KO mice show decreased tissue perfusion compared to WT mice by using laser speckle contrast imaging. To study both the acute and long-term effects of sodium nitrite (0, 0.1, 1, and 10 mg/kg) on peripheral blood flow and systemic blood pressure, a bolus of nitrite was delivered intraperitoneally every 24 h over 4 consecutive days. We found that nitrite administration resulted in a dose-dependent and acute increase in peripheral blood flow in eNOS KO mice but had no effects in WT mice. The nitrite induced changes in tissue perfusion were transient, as determined by intraindividual comparisons of tissue perfusion 24-h after injection. Accordingly, 10 mg/kg sodium nitrite acutely decreased blood pressure in eNOS KO mice but not in WT mice as determined by invasive Millar catheterization. Interestingly, we found the vasodilatory effects of nitrite to be inversely correlated to baseline tissue perfusion. These results demonstrate the nitrite acutely recovers hypoperfusion and hypertension in global eNOS KO mice and suggest the vasodilatory actions of nitrite are dependent upon tissue hypoperfusion.


Subject(s)
Mice, Knockout , Nitric Oxide Synthase Type III , Animals , Nitric Oxide Synthase Type III/metabolism , Mice , Hemodynamics/drug effects , Sodium Nitrite/pharmacology , Male , Blood Pressure/drug effects , Mice, Inbred C57BL , Nitrites/pharmacology , Regional Blood Flow/drug effects
2.
Nutrients ; 16(16)2024 Aug 15.
Article in English | MEDLINE | ID: mdl-39203851

ABSTRACT

This study aimed to assess ginger extract's impact on ocular and peripheral blood flow and its potential to alleviate eye fatigue and shoulder stiffness. This study included 100 healthy individuals aged 20-73 years with eye fatigue and shoulder stiffness. Participants were randomly assigned to receive either placebo capsules or ginger extract capsules daily for eight weeks. Ocular blood flow, peripheral blood flow, eye fatigue (visual analog scale [VAS]), shoulder stiffness (VAS), body warmth (VAS), and shoulder muscle stiffness were assessed at weeks 0, 4, and 8, respectively. No improvement in ocular blood flow was observed under the study conditions. Conversely, peripheral blood flow in deep areas was enhanced in females (p = 0.033). Subgroup analysis by age (≥51 or <51 years) revealed that ginger's effect on enhancing peripheral blood flow in deep vessels was restricted in females under 51 (p = 0.017). Similarly, subjective complaints of eye fatigue and shoulder stiffness were improved by ginger consumption in females under 51. Body warmth was favorably changed significantly in males ≥51 years due to ginger consumption. The muscle stiffness showed no statistically significant changes. In conclusion, ginger consumption reduces eye fatigue and shoulder stiffness by enhancing peripheral blood flow in relatively young females.


Subject(s)
Plant Extracts , Zingiber officinale , Humans , Zingiber officinale/chemistry , Female , Middle Aged , Male , Plant Extracts/pharmacology , Adult , Double-Blind Method , Aged , Young Adult , Shoulder , Eye/drug effects , Asthenopia/drug therapy , Regional Blood Flow/drug effects
3.
J Am Heart Assoc ; 13(16): e030775, 2024 Aug 20.
Article in English | MEDLINE | ID: mdl-39119951

ABSTRACT

BACKGROUND: Obesity is associated with resistance to the metabolic (glucose uptake) and vascular (nitric-oxide mediated dilation and microvascular recruitment) actions of insulin. These vascular effects contribute to insulin sensitivity by increasing tissue delivery of glucose. Studies by us and others suggest that sympathetic activation contributes to insulin resistance to glucose uptake. Here we tested the hypothesis that sympathetic activation contributes to impaired insulin-mediated vasodilation in adult subjects with obesity. METHODS AND RESULTS: In a randomized crossover study, we used a euglycemic hyperinsulinemic clamp in 12 subjects with obesity to induce forearm arterial vasodilation (forearm blood flow) and microvascular recruitment (contrast-enhanced ultrasonography) during an intrabrachial infusion of saline (control) or phentolamine (sympathetic blockade). Insulin increased forearm blood flow on both study days (from 2.21±1.22 to 4.89±4.21 mL/100 mL per min, P=0.003 and from 2.42±0.89 to 7.19±3.35 mL/100 mL per min, P=0.002 for the intact and blocked day, respectively). Sympathetic blockade with phentolamine resulted in a significantly greater increase in microvascular flow velocity (∆microvascular flow velocity: 0.23±0.65 versus 2.51±3.01 arbitrary intensity units (AIU/s) for saline and phentolamine respectively, P=0.005), microvascular blood volume (∆microvascular blood volume: 1.69±2.45 versus 3.76±2.93 AIU, respectively, P=0.05), and microvascular blood flow (∆microvascular blood flow: 0.28±0.653 versus 2.51±3.01 AIU2/s, respectively, P=0.0161). To evaluate if this effect was not due to nonspecific vasodilation, we replicated the study in 6 subjects with obesity comparing intrabrachial infusion of phentolamine to sodium nitroprusside. At doses that produced similar increases in forearm blood flow, insulin-induced changes in microvascular flow velocity were greater during phentolamine than sodium nitroprusside (%microvascular flow velocity=58% versus 29%, respectively, P=0.031). CONCLUSIONS: We conclude that sympathetic activation impairs insulin-mediated microvascular recruitment in adult subjects with obesity.


Subject(s)
Cross-Over Studies , Forearm , Insulin , Microcirculation , Obesity , Phentolamine , Regional Blood Flow , Sympathetic Nervous System , Vasodilation , Humans , Forearm/blood supply , Male , Phentolamine/pharmacology , Female , Obesity/physiopathology , Vasodilation/drug effects , Vasodilation/physiology , Adult , Sympathetic Nervous System/physiopathology , Sympathetic Nervous System/drug effects , Regional Blood Flow/drug effects , Microcirculation/drug effects , Blood Flow Velocity , Middle Aged , Glucose Clamp Technique , Insulin Resistance , Autonomic Nerve Block/methods
4.
Int Ophthalmol ; 44(1): 311, 2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38963456

ABSTRACT

PURPOSE: To study the effect of brimonidine on vascular density and flow index of optic nerve head (ONH) and macula in primary open angle glaucoma (POAG) using optical coherence tomography angiography (OCTA). METHODS: Twenty-three brimonidine-naïve POAG patients were started on brimonidine. They underwent OCTA ONH and macula before commencing brimonidine and one month thereafter. Systemic arterial blood pressure (SABP) and intraocular pressure (IOP) were measured at each visit to calculate mean ocular perfusion pressure (MOPP). The OCT angiograms were analyzed using ImageJ software to calculate ONH and macular flow indices. RESULTS: Thirty-seven eyes (23 patients) with a mean age of 56.7 ± 12.49 years were included of whom 60.8% were males. Brimonidine was associated with an increase in the superficial flow index (SFI) (P-value = 0.02) and optic nerve head flow index (ONHFI) (P-value = 0.01). Also, superficial vascular density (SVD) for whole image, superior-hemi and fovea increased (P-value = 0.03, 0.02, 0.03 respectively). ONH inferior-hemi vascular density decreased (P-value = 0.01) despite an increase in inferior quadrant retinal nerve fiber layer thickness (RNFLT) (P-value = 0.03). There was no statistically significant correlation between flow indices and MOPP at baseline and follow-up. A moderate negative correlation was found between SVD and DVD at the fovea and MOPP at baseline and follow-up (P-value = 0.03, 0.05) (P-value = 0.02, 0.01) respectively. CONCLUSIONS: Brimonidine was associated with an increase in SFI, ONHFI and SVD indicating improved GCC and RNFL perfusion in POAG. Despite the increase in inferior quadrant RNFLT, the concomitant decrease in inferior-hemi ONHVD precluded a conclusion of hemodynamically-mediated improvement of RNFLT.


Subject(s)
Brimonidine Tartrate , Fluorescein Angiography , Glaucoma, Open-Angle , Intraocular Pressure , Macula Lutea , Optic Disk , Retinal Vessels , Tomography, Optical Coherence , Humans , Glaucoma, Open-Angle/physiopathology , Glaucoma, Open-Angle/drug therapy , Glaucoma, Open-Angle/diagnosis , Male , Optic Disk/blood supply , Brimonidine Tartrate/administration & dosage , Brimonidine Tartrate/pharmacology , Brimonidine Tartrate/therapeutic use , Middle Aged , Female , Tomography, Optical Coherence/methods , Macula Lutea/blood supply , Macula Lutea/diagnostic imaging , Intraocular Pressure/physiology , Intraocular Pressure/drug effects , Retinal Vessels/diagnostic imaging , Retinal Vessels/physiopathology , Retinal Vessels/drug effects , Fluorescein Angiography/methods , Regional Blood Flow/physiology , Regional Blood Flow/drug effects , Aged , Fundus Oculi , Prospective Studies , Visual Fields/physiology , Retinal Ganglion Cells/pathology , Retinal Ganglion Cells/drug effects , Antihypertensive Agents/therapeutic use , Nerve Fibers/pathology , Nerve Fibers/drug effects , Adult , Follow-Up Studies
5.
J Appl Physiol (1985) ; 137(2): 421-428, 2024 Aug 01.
Article in English | MEDLINE | ID: mdl-38961822

ABSTRACT

To determine whether using nicotine exacerbates exertional heat strain through an increased metabolic heat production (Hprod) or decreased skin blood flow (SkBF), 10 nicotine-naïve trained males [37 ± 12 yr; peak oxygen consumption (V̇o2peak): 66 ± 10 mL·min-1·kg-1] completed four trials at 20°C and 30°C following overnight transdermal nicotine (7 mg·24 h-1) and placebo use in a crossover, double-blind design. They cycled for 60 min (55% V̇o2peak) followed by a time trial (∼75% V̇o2peak) during which measures of gastrointestinal (Tgi) and mean weighted skin ([Formula: see text]sk) temperatures, SkBF, Hprod, and mean arterial pressure (MAP) were made. The difference in ΔTgi between nicotine and placebo trials was greater during 30°C (0.4 ± 0.5°C) than 20°C (0.1 ± 0.7°C), with [Formula: see text]sk higher during nicotine than placebo trials (0.5 ± 0.5°C, P = 0.02). SkBF became progressively lower during nicotine than placebo trials (P = 0.01) and progressively higher during 30°C than 20°C trials (P < 0.01); MAP increased from baseline (P < 0.01) and remained elevated in all trials. The difference in Hprod between 30°C and 20°C trials was lower during nicotine than placebo (P = 0.01) and became progressively higher during 30°C than 20°C trials with exercise duration (P = 0.03). Mean power output during the time trial was lower during 30°C than 20°C trials (24 ± 25 W, P = 0.02), and although no effect of nicotine was observed (P > 0.59), two participants (20%) were unable to complete their 30°C nicotine trials as one reached the ethical limit for Tgi (40.0°C), whereas the other withdrew due to "nausea and chills" (Tgi = 39.7°C). These results demonstrate that nicotine use increases thermal strain and risk of exertional heat exhaustion by reducing SkBF.NEW & NOTEWORTHY In naïve participants, acute nicotine use exerts a hyperthermic effect that increases the risk of heat exhaustion during exertional heat strain, which is driven by a blunted skin blood flow response. This has implications for 1) populations that face exertional heat strain and demonstrate high nicotine use (e.g., athletes and military, 25%-50%) and 2) study design whereby screening and exclusion for nicotine use or standardization of prior use (e.g., overnight abstinence) is encouraged.


Subject(s)
Cross-Over Studies , Nicotine , Oxygen Consumption , Skin , Humans , Male , Nicotine/adverse effects , Nicotine/administration & dosage , Double-Blind Method , Adult , Oxygen Consumption/drug effects , Oxygen Consumption/physiology , Skin/drug effects , Skin/blood supply , Hot Temperature , Physical Exertion/physiology , Physical Exertion/drug effects , Middle Aged , Skin Temperature/drug effects , Skin Temperature/physiology , Exercise/physiology , Heat Stress Disorders/physiopathology , Thermogenesis/drug effects , Thermogenesis/physiology , Regional Blood Flow/drug effects , Regional Blood Flow/physiology
6.
J Dermatol Sci ; 114(3): 133-140, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38834380

ABSTRACT

BACKGROUND: Mucopolysaccharide polysulfate (MPS) is widely used as an active ingredient in topical preparations for the treatment of asteatosis and blood flow disorders. Although topical MPS products can increase cutaneous blood flow (CBF), the underlying mechanism remains unclear. OBJECTIVE: In this study, we aimed to elucidate how MPS increases CBF. We investigated the association of nitric oxide (NO), a powerful mediator associated with increased local blood volume, with the blood flow-accelerating action of MPS in mice. In addition, we verified the effects of MPS on NO production in different skin cell types, such as keratinocytes (KCs), endothelial cells (ECs), and dermal fibroblasts (DFs). METHODS: We used raster-scanning optoacoustic imaging mesoscopy to observe in vivo changes in the skin blood volume. NO production was determined in each cell using an NO indicator. An enzyme-linked immunoassay was used to measure the phosphorylated nitric oxide synthase (NOS) levels in ECs, DFs, and KCs in the presence or absence of MPS. RESULTS: Topical application of MPS increased the skin blood volume in mice, and this increase was abolished through the addition of NOS inhibitors. MPS promoted the dose-dependent production of NO in various cells, which caused alterations in the phosphorylation state of NOS. CONCLUSION: Our findings demonstrate that MPS promotes an increase in skin blood volume and NO production in various skin cell types. These results suggest that MPS can potentially accelerate CBF through the NO biosynthesis pathway in different skin cell types.


Subject(s)
Fibroblasts , Nitric Oxide , Skin , Animals , Nitric Oxide/metabolism , Mice , Skin/drug effects , Skin/blood supply , Skin/metabolism , Fibroblasts/metabolism , Fibroblasts/drug effects , Keratinocytes/drug effects , Keratinocytes/metabolism , Humans , Male , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Administration, Cutaneous , Regional Blood Flow/drug effects , Cells, Cultured , Mice, Inbred C57BL
7.
Sci Rep ; 14(1): 13798, 2024 06 14.
Article in English | MEDLINE | ID: mdl-38877041

ABSTRACT

We assessed the short-term effects of switching from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF) on ocular blood flow in patients with treatment-resistant diabetic macular edema (DME). The medical records of 15 patients with DME who had received IVA injection ≥ 3 months before were retrospectively reviewed. The best-corrected visual acuity, central macular thickness (CMT) on optical coherence tomography, and mean blur rate (MBR) of all disc areas on laser speckle flowgraphy were measured before, 1 week after, and 4 weeks after IVA and IVF, respectively. The changes in visual acuity showed no significant difference after switching from IVA to IVF (P = 0.732). The mean CMT decreased significantly during the follow-up period (both P < 0.001). MBR showed no significant difference during the follow-up period (P = 0.26). However, it decreased significantly 4 weeks after IVF (P = 0.01) compared with the baseline value, but not 4 weeks after IVA (P = 0.074). A significant association was observed between decreased MBR and decreased CMT in patients who received IVF (correlation coefficient: 0.501, P = 0.005) but not in those who received IVA (P = 0.735). Thus, IVF maintained ocular blood flow reduction, although no significant differences in visual acuity and CMT changes were observed compared to IVA.


Subject(s)
Diabetic Retinopathy , Intravitreal Injections , Macular Edema , Receptors, Vascular Endothelial Growth Factor , Recombinant Fusion Proteins , Humans , Macular Edema/drug therapy , Macular Edema/etiology , Male , Female , Recombinant Fusion Proteins/administration & dosage , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Middle Aged , Diabetic Retinopathy/drug therapy , Aged , Retrospective Studies , Visual Acuity/drug effects , Tomography, Optical Coherence , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/therapeutic use , Regional Blood Flow/drug effects , Eye/blood supply , Eye/drug effects
8.
Am J Physiol Heart Circ Physiol ; 327(2): H364-H369, 2024 08 01.
Article in English | MEDLINE | ID: mdl-38847757

ABSTRACT

The transcriptional regulator nuclear factor-κB (NF-κB) is a mediator of endothelial dysfunction. Inhibiting NF-κB with salsalate is used to investigate inflammatory mechanisms contributing to accelerated cardiovascular disease risk. However, in the absence of disease, inhibition of NF-κB can impact redox mechanisms, resulting in paradoxically decreased endothelial function. This study aimed to measure microvascular endothelial function during inhibition of the transcriptional regulator NF-κB in reproductive-aged healthy women. In a randomized, single-blind, crossover, placebo-controlled design, nine healthy women were randomly assigned oral salsalate (1,500 mg, twice daily) or placebo treatments for 5 days. Subjects underwent graded perfusion with the endothelium-dependent agonist acetylcholine (ACh, 10-10 to 10-1 M, 33°C) alone and in combination with 15 mM NG-nitro-l-arginine methyl ester [l-NAME; nonselective nitric oxide (NO) synthase inhibitor] through intradermal microdialysis. Laser-Doppler flux was measured over each microdialysis site, and cutaneous vascular conductance (CVC) was calculated as flux divided by mean arterial pressure and normalized to site-specific maximum (CVC%max; 28 mM sodium nitroprusside + 43°C). The l-NAME sensitive component was calculated as the difference between the areas under the dose-response curves. During the placebo and salsalate treatments, the l-NAME sites were reduced compared with the control sites (both P < 0.0001). Across treatments, there was a significant difference between the control and l-NAME sites, where both sites shifted upward following salsalate treatment (both P < 0.0001), whereas the l-NAME-sensitive component was not different (P = 0.94). These data demonstrate that inhibition of the transcriptional regulator NF-κB improves cutaneous microvascular function in reproductive-aged healthy women through non-NO-dependent mechanisms.NEW & NOTEWORTHY The transcription factor nuclear factor-κB (NF-κB) regulates multiple aspects of innate and adaptive immunity by encoding for genes that participate in inflammation and impact endothelial function following NF-κB inhibition with salsalate treatment. Our results show that cutaneous microvascular function is increased through non-nitric oxide (NO)-dependent mechanisms following salsalate treatment in reproductive-aged healthy women.


Subject(s)
Cross-Over Studies , Microcirculation , NF-kappa B , Nitric Oxide , Skin , Humans , Female , Adult , Skin/blood supply , Skin/drug effects , Skin/metabolism , NF-kappa B/metabolism , Single-Blind Method , Microcirculation/drug effects , Nitric Oxide/metabolism , NG-Nitroarginine Methyl Ester/pharmacology , Vasodilation/drug effects , Young Adult , Acetylcholine/pharmacology , Healthy Volunteers , Vasodilator Agents/pharmacology , Enzyme Inhibitors/pharmacology , Salicylates/pharmacology , Microvessels/drug effects , Microvessels/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Regional Blood Flow/drug effects
9.
Nutrients ; 16(12)2024 Jun 19.
Article in English | MEDLINE | ID: mdl-38931289

ABSTRACT

Endothelial dysfunction decreases exercise limb blood flow (BF) and muscle oxygenation. Acute L-Citrulline supplementation (CIT) improves muscle tissue oxygen saturation index (TSI) and deoxygenated hemoglobin (HHb) during exercise. Although CIT improves endothelial function (flow-mediated dilation [FMD]) in hypertensive women, the impact of CIT on exercise BF and muscle oxygenation (TSI) and extraction (HHb) are unknown. We examined the effects of CIT (10 g/day) and a placebo for 4 weeks on blood pressure (BP), arterial vasodilation (FMD, BF, and vascular conductance [VC]), and forearm muscle oxygenation (TSI and HHb) at rest and during exercise in 22 hypertensive postmenopausal women. Compared to the placebo, CIT significantly (p < 0.05) increased FMD (Δ-0.7 ± 0.6% vs. Δ1.6 ± 0.7%) and reduced aortic systolic BP (Δ3 ± 5 vs. Δ-4 ± 6 mmHg) at rest and improved exercise BF (Δ17 ± 12 vs. Δ48 ± 16 mL/min), VC (Δ-21 ± 9 vs. Δ41 ± 14 mL/mmHg/min), TSI (Δ-0.84 ± 0.58% vs. Δ1.61 ± 0.46%), and HHb (Δ1.03 ± 0.69 vs. Δ-2.76 ± 0.77 µM). Exercise BF and VC were positively correlated with improved FMD and TSI during exercise (all p < 0.05). CIT improved exercise artery vasodilation and muscle oxygenation via increased endothelial function in hypertensive postmenopausal women.


Subject(s)
Citrulline , Dietary Supplements , Exercise , Hand Strength , Hypertension , Muscle, Skeletal , Postmenopause , Regional Blood Flow , Vasodilation , Humans , Female , Citrulline/pharmacology , Middle Aged , Hypertension/physiopathology , Hypertension/drug therapy , Muscle, Skeletal/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/blood supply , Hand Strength/physiology , Vasodilation/drug effects , Regional Blood Flow/drug effects , Aged , Exercise/physiology , Blood Pressure/drug effects , Oxygen/blood , Oxygen/metabolism , Oxygen Consumption/drug effects , Double-Blind Method , Endothelium, Vascular/drug effects
10.
Am J Physiol Heart Circ Physiol ; 327(1): H000, 2024 07 01.
Article in English | MEDLINE | ID: mdl-38787381

ABSTRACT

Systemic insulin increases muscle sympathetic nerve activity (MSNA) via both central actions within the brainstem and peripheral activation of the arterial baroreflex. Augmented MSNA during hyperinsulinemia likely restrains peripheral vasodilation and contributes to the maintenance of blood pressure (BP). However, in the absence of insulin action within the peripheral vasculature, whether central insulin stimulation increases MSNA and influences peripheral hemodynamics in humans remains unknown. Herein, we hypothesized intranasal insulin administration would increase MSNA and BP in healthy young adults. Participants were assigned to time control [TC, n = 13 (5 females/8 males), 28 ± 1 yr] or 160 IU of intranasal insulin administered over 5 min [n = 15 (5 females/10 males), 26 ± 2 yr]; five (1 female/4 males) participants completed both conditions. MSNA (fibular microneurography), BP (finger photoplethysmography), and leg blood flow (LBF, femoral Doppler ultrasound) were assessed at baseline, and 15 and 30 min following insulin administration. Leg vascular conductance [LVC = (LBF ÷ mean BP) × 100] was calculated. Venous insulin and glucose concentrations remained unchanged throughout (P > 0.05). Following intranasal insulin administration, MSNA (burst frequency; baseline = 100%; minute 15, 121 ± 8%; minute 30, 118 ± 6%; P = 0.009, n = 7) and mean BP (baseline = 100%; minute 15, 103 ± 1%; minute 30, 102 ± 1%; P = 0.003) increased, whereas LVC decreased (baseline = 100%; minute 15, 93 ± 3%; minute 30, 99 ± 3%; P = 0.03). In contrast, MSNA, mean BP, and LVC were unchanged in TC participants (P > 0.05). We provide the first evidence that intranasal insulin administration in healthy young adults acutely increases MSNA and BP and decreases LVC. These results enhance mechanistic understanding of the sympathetic and peripheral hemodynamic response to insulin.NEW & NOTEWORTHY Systemic insulin increases muscle sympathetic nerve activity (MSNA) via central actions within the brainstem and peripheral activation of the arterial baroreflex. In the absence of peripheral insulin action, whether central insulin stimulation increases MSNA and influences peripheral hemodynamics in humans was unknown. We provide the first evidence that intranasal insulin administration increases MSNA and blood pressure and reduces leg vascular conductance. These results enhance mechanistic understanding of the sympathetic and hemodynamic response to insulin.


Subject(s)
Administration, Intranasal , Insulin , Muscle, Skeletal , Sympathetic Nervous System , Humans , Male , Female , Insulin/administration & dosage , Insulin/blood , Sympathetic Nervous System/drug effects , Adult , Muscle, Skeletal/innervation , Muscle, Skeletal/blood supply , Muscle, Skeletal/drug effects , Blood Pressure/drug effects , Regional Blood Flow/drug effects , Blood Glucose/metabolism , Blood Glucose/drug effects , Healthy Volunteers , Young Adult , Baroreflex/drug effects
11.
Eur J Nutr ; 63(6): 2379-2387, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38809323

ABSTRACT

PURPOSE: Dietary nitrate (NO3-) supplementation enhances muscle blood flow and metabolic efficiency in hypoxia, however, its efficacy on neuromuscular function and specifically, the effect on motor unit (MU) activity is less clear. We investigated whether NO3- supplementation affected MU activity following a 3 min sustained ischemic contraction and whether this is influenced by blood flow restriction (BFR) during the recovery period. METHOD: In a randomized, double-blinded, cross-over design, 14 males (mean ± SD, 25 ± 6 years) completed two trials following 5 days of supplementation with NO3--rich (NIT) or NO3--depleted (PLA) beetroot juice to modify plasma nitrite (NO2-) concentration (482 ± 92 vs. 198 ± 48 nmol·L-1, p < 0.001). Intramuscular electromyography was used to assess MU potential (MUP) size (duration and area) and mean firing rates (MUFR) during a 3 min submaximal (25% MVC) isometric contraction with BFR. These variables were also assessed during a 90 s recovery period with the first half completed with, and the second half completed without, BFR. RESULTS: The change in MUP area and MUFR, did not differ between conditions (all p > 0.05), but NIT elicited a reduction in MUP recovery time during brief isometric contractions (p < 0.001), and during recoveries with (p = 0.002) and without (p = 0.012) BFR. CONCLUSION: These novel observations improve understanding of the effects of NO3- on the recovery of neuromuscular function post-exercise and might have implications for recovery of muscle contractile function. TRIAL REGISTRATION: The study was registered on clinicaltrials.gov with ID of NCT05993715 on August 08, 2023.


Subject(s)
Cross-Over Studies , Dietary Supplements , Electromyography , Muscle, Skeletal , Nitrates , Humans , Male , Double-Blind Method , Nitrates/administration & dosage , Nitrates/pharmacology , Nitrates/blood , Adult , Young Adult , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiology , Electromyography/methods , Muscle Contraction/drug effects , Isometric Contraction/drug effects , Isometric Contraction/physiology , Fruit and Vegetable Juices , Beta vulgaris/chemistry , Ischemia/physiopathology , Regional Blood Flow/drug effects
12.
Exp Physiol ; 109(6): 992-1003, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38711207

ABSTRACT

Young individuals with post-traumatic stress disorder (PTSD) display peripheral vascular and autonomic nervous system dysfunction, two factors potentially stemming from a redox imbalance. It is currently unclear if these aforementioned factors, observed at rest, alter peripheral haemodynamic responses to exercise in this population. This study examined haemodynamic responses to handgrip exercise in young individuals with PTSD following acute antioxidant (AO) supplementation. Thirteen young individuals with PTSD (age 23 ± 3 years), and 13 age- and sex-matched controls (CTRL) participated in the study. Exercise-induced changes to arm blood flow (BF), mean arterial pressure (MAP) and vascular conductance (VC) were evaluated across two workloads of rhythmic handgrip exercise (3 and 6 kg). The PTSD group participated in two visits, consuming either a placebo (PL) or AO prior to their visits. The PTSD group demonstrated significantly lower VC (P = 0.04) across all exercise workloads (vs. CTRL), which was significantly improved following AO supplementation. In the PTSD group, AO supplementation improved VC in participants possessing the lowest VC responses to handgrip exercise, with AO supplementation significantly improving VC responses (3 and 6 kg: P < 0.01) by blunting elevated exercise-induced MAP responses (3 kg: P = 0.01; 6 kg: P < 0.01). Lower VC responses during handgrip exercise were improved following AO supplementation in young individuals with PTSD. AO supplementation was associated with a blunting of exercise-induced MAP responses in individuals with PTSD displaying elevated MAP responses. This study revealed that young individuals with PTSD exhibit abnormal, peripherally mediated exercise responses that may be linked to a redox imbalance.


Subject(s)
Antioxidants , Dietary Supplements , Exercise , Hand Strength , Stress Disorders, Post-Traumatic , Humans , Hand Strength/physiology , Antioxidants/administration & dosage , Male , Female , Young Adult , Stress Disorders, Post-Traumatic/physiopathology , Exercise/physiology , Adult , Hemodynamics/drug effects , Hemodynamics/physiology , Blood Pressure/physiology , Blood Pressure/drug effects , Regional Blood Flow/physiology , Regional Blood Flow/drug effects
13.
Exp Physiol ; 109(6): 980-991, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38606906

ABSTRACT

Increasing placental perfusion (PP) could improve outcomes of growth-restricted fetuses. One way of increasing PP may be by using phosphodiesterase (PDE)-5 inhibitors, which induce vasodilatation of vascular beds. We used a combination of clinically relevant magnetic resonance imaging (MRI) techniques to characterize the impact that tadalafil infusion has on maternal, placental and fetal circulations. At 116-117 days' gestational age (dGA; term, 150 days), pregnant ewes (n = 6) underwent fetal catheterization surgery. At 120-123 dGA ewes were anaesthetized and MRI scans were performed during three acquisition windows: a basal state and then ∼15-75 min (TAD 1) and ∼75-135 min (TAD 2) post maternal administration (24 mg; intravenous bolus) of tadalafil. Phase contrast MRI and T2 oximetry were used to measure blood flow and oxygen delivery. Placental diffusion and PP were assessed using the Diffusion-Relaxation Combined Imaging for Detailed Placental Evaluation-'DECIDE' technique. Uterine artery (UtA) blood flow when normalized to maternal left ventricular cardiac output (LVCO) was reduced in both TAD periods. DECIDE imaging found no impact of tadalafil on placental diffusivity or fetoplacental blood volume fraction. Maternal-placental blood volume fraction was increased in the TAD 2 period. Fetal D O 2 ${D_{{{\mathrm{O}}_2}}}$ and V ̇ O 2 ${\dot V_{{{\mathrm{O}}_2}}}$ were not affected by maternal tadalafil administration. Maternal tadalafil administration did not increase UtA blood flow and thus may not be an effective vasodilator at the level of the UtAs. The increased maternal-placental blood volume fraction may indicate local vasodilatation of the maternal intervillous space, which may have compensated for the reduced proportion of UtA D O 2 ${D_{{{\mathrm{O}}_2}}}$ .


Subject(s)
Oxygen , Placenta , Placental Circulation , Tadalafil , Uterine Artery , Animals , Female , Tadalafil/pharmacology , Tadalafil/administration & dosage , Pregnancy , Sheep , Uterine Artery/drug effects , Placenta/drug effects , Placenta/blood supply , Placental Circulation/drug effects , Oxygen/blood , Regional Blood Flow/drug effects , Phosphodiesterase 5 Inhibitors/pharmacology , Phosphodiesterase 5 Inhibitors/administration & dosage , Magnetic Resonance Imaging , Fetus/blood supply , Fetus/drug effects
14.
Exp Physiol ; 109(5): 779-790, 2024 May.
Article in English | MEDLINE | ID: mdl-38445814

ABSTRACT

Endothelial dysfunction develops with age and may precede cardiovascular disease. Animal data suggest that T-type calcium channels play an important role in endothelial function, but data from humans are lacking. This study included 15 healthy, sedentary, elderly males for a double blinded, randomized controlled trial. For 8 weeks, they were given 40 mg/day of either efonidipine (L- and T-type calcium channel blocker (CCB)) or nifedipine (L-type CCB). Vascular function was evaluated by graded femoral arterial infusions of acetylcholine (ACh; endothelium-dependent vasodilator) and sodium nitroprusside (endothelium-independent vasodilator) both with and without co-infusion of N-acetylcysteine (NAC; antioxidant). We measured leg blood flow and mean arterial pressure and calculated leg vascular conductance to evaluate the leg vascular responses. Despite no significant change in blood pressure in either group, we observed higher leg blood flow responses (Δ 0.43 ± 0.45 l/min, P = 0.006) and leg vascular conductance (Δ 5.38 ± 5.67 ml/min/mmHg, P = 0.005) to intra-arterial ACh after efonidipine, whereas there was no change in the nifedipine group, and no differences between groups. We found no upregulation of endothelial nitric oxide synthase in vastus lateralis muscle biopsies within or between groups. Smooth muscle cell responsiveness was unaltered by efonidipine or nifedipine. Intravenous co-infusion of NAC did not affect endothelium-dependent vasodilatation in either of the CCB groups. These results suggest that 8 weeks' inhibition of T- and L-type calcium channels augments endothelium-dependent vasodilatory function in healthy elderly males. Further studies are required to elucidate if T-type calcium channel inhibition can counteract endothelial dysfunction.


Subject(s)
Calcium Channel Blockers , Calcium Channels, T-Type , Endothelium, Vascular , Nifedipine , Nitrophenols , Humans , Male , Calcium Channels, T-Type/metabolism , Calcium Channels, T-Type/drug effects , Aged , Calcium Channel Blockers/pharmacology , Nifedipine/pharmacology , Pilot Projects , Double-Blind Method , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiology , Dihydropyridines/pharmacology , Vasodilation/drug effects , Vasodilation/physiology , Vasodilator Agents/pharmacology , Blood Pressure/drug effects , Blood Pressure/physiology , Regional Blood Flow/drug effects , Regional Blood Flow/physiology , Organophosphorus Compounds/pharmacology , Acetylcholine/pharmacology , Leg/blood supply , Nitroprusside/pharmacology , Middle Aged
15.
Kurume Med J ; 69(3.4): 167-174, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38233183

ABSTRACT

OBJECTIVE: Oxidative damage is observed in the ischemic limbs of patients with arteriosclerosis obliterans. We investigated whether pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, reduced oxidative stress in ischemic limbs and consequently rescued limb damage in model mice. MATERIALS AND METHODS: We surgically induced hind-limb ischemia in mice and orally administered pemafibrate solution (P-05 group, 0.5 mg/kg/day; P-10 group, 1.0 mg/kg/day) or control solution (control group). Seven days after the surgery, differences in reactive oxygen species (ROS) contents, antioxidative enzyme and transcription factor expression, blood flow, and capillary density in ischemic limbs were assessed. RESULTS: Tissue ROS levels were lower in the P-05 and P-10 groups compared with those in the control group. Although the tissue expression levels of nuclear factor-erythroid 2-related factor 2 increased in the P-10 group compared with that in the control group, no corresponding changes were observed in the tissue expression of four antioxidative enzymes. The limb salvage rates and capillary densities in ischemic limbs were higher in the P-05 and P-10 groups than that in the control group. CONCLUSION: Pemafibrate treatment reduced oxidative stress and augmented angiogenesis in ischemic limbs, contributing to prevention of limb damage in mice.


Subject(s)
Benzoxazoles , Butyrates , Disease Models, Animal , Hindlimb , Ischemia , Neovascularization, Physiologic , Oxidative Stress , Reactive Oxygen Species , Animals , Oxidative Stress/drug effects , Benzoxazoles/pharmacology , Benzoxazoles/therapeutic use , Ischemia/drug therapy , Ischemia/metabolism , Neovascularization, Physiologic/drug effects , Male , Hindlimb/blood supply , Reactive Oxygen Species/metabolism , Butyrates/pharmacology , Butyrates/therapeutic use , Mice , Antioxidants/pharmacology , NF-E2-Related Factor 2/metabolism , Regional Blood Flow/drug effects , PPAR alpha/metabolism , Limb Salvage , Angiogenesis
16.
Endocrinology ; 163(3)2022 03 01.
Article in English | MEDLINE | ID: mdl-35084435

ABSTRACT

Skeletal muscle insulin resistance is a hallmark of individuals with type 2 diabetes mellitus (T2D). In healthy individuals insulin stimulates vasodilation, which is markedly blunted in T2D; however, the mechanism(s) remain incompletely understood. Investigations in rodents indicate augmented endothelin-1 (ET-1) action as a major contributor. Human studies have been limited to young obese participants and focused exclusively on the ET-1 A (ETA) receptor. Herein, we have hypothesized that ETA receptor antagonism would improve insulin-stimulated vasodilation and glucose uptake in T2D, with further improvements observed during concurrent ETA + ET-1 B (ETB) antagonism. Arterial pressure (arterial line), leg blood flow (LBF; Doppler), and leg glucose uptake (LGU) were measured at rest, during hyperinsulinemia alone, and hyperinsulinemia with (1) femoral artery infusion of BQ-123, the selective ETA receptor antagonist (n = 10 control, n = 9 T2D) and then (2) addition of BQ-788 (selective ETB antagonist) for blockade of ETA and ETB receptors (n = 7 each). The LBF responses to hyperinsulinemia alone tended to be lower in T2D (controls: ∆161 ±â€…160 mL/minute; T2D: ∆58 ±â€…43 mL/minute, P = .08). BQ-123 during hyperinsulinemia augmented LBF to a greater extent in T2D (% change: controls: 14 ±â€…23%; T2D: 38 ±â€…21%, P = .029). LGU following BQ-123 increased similarly between groups (P = .85). Concurrent ETA + ETB antagonism did not further increase LBF or LGU in either group. Collectively, these findings suggest that during hyperinsulinemia ETA receptor activation restrains vasodilation more in T2D than controls while limiting glucose uptake similarly in both groups, with no further effect of ETB receptors (NCT04907838).


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Endothelin Receptor Antagonists/pharmacology , Glucose/metabolism , Hyperinsulinism/metabolism , Leg/blood supply , Receptor, Endothelin A/metabolism , Regional Blood Flow/drug effects , Blood Pressure/drug effects , Endothelin B Receptor Antagonists/pharmacology , Female , Humans , Male , Middle Aged , Oligopeptides/pharmacology , Peptides, Cyclic/pharmacology , Piperidines/pharmacology , Regional Blood Flow/physiology , Vasodilation/drug effects
17.
Pharmacol Res ; 175: 105905, 2022 01.
Article in English | MEDLINE | ID: mdl-34798267

ABSTRACT

The objective of this systematic review and meta-analysis of controlled trials was to assess the long-term effect of grape seed extract (GSE) supplementation on flow-mediated dilation (FMD), systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) in adults. Web of Science, Scopus, Medline, Cochrane Library, and Google Scholar were searched up to May 24, 2021. Nineteen trials were included in this study. Weighted mean difference (WMD) and 95% confidence interval (CI) were calculated using a random-effects model. GSE supplementation significantly reduced DBP (WMD: -2.20 mmHg, 95% CI: -3.79 to -0.60, I2 = 88.8%) and HR (WMD: -1.25 bpm, 95% CI: -2.32 to -0.19, I2 = 59.5%) but had no significant effects on FMD (WMD: 1.02%, 95% CI: -0.62 to 2.66, I2 = 92.0%) and SBP (WMD: -3.55 mmHg, 95% CI: -7.59 to 0.49, I2 = 97.4%). Subgroup analysis revealed that the dose and duration of GSE administration and the characteristics of study participants could be sources of between-study heterogeneity. Significant non-linear relationships were found between DBP and the duration of GSE supplementation (P = 0.044) and its dose (P = 0.007). In conclusion, GSE may be beneficial for individuals with or at risk of cardiovascular disease because it may have hypotensive and HR-lowering properties.


Subject(s)
Blood Pressure/drug effects , Heart Rate/drug effects , Plant Extracts/administration & dosage , Vitis , Brachial Artery/drug effects , Brachial Artery/physiology , Dose-Response Relationship, Drug , Humans , Randomized Controlled Trials as Topic , Regional Blood Flow/drug effects , Seeds , Vasodilation/drug effects
18.
Toxicol Appl Pharmacol ; 435: 115851, 2022 01 15.
Article in English | MEDLINE | ID: mdl-34971666

ABSTRACT

There has been a significant research interest in nanocrystals as a promising technology for improving the therapeutic efficacy of poorly water-soluble drugs, such as resveratrol. Little is known about the interaction of nanocrystals with biological tissue. The aim of this study was to investigate the potential use of resveratrol (RSV) and its nanocrystals (NANO-RSV) as antitumor agents in Ehrlich ascites tumour (EAT)-bearing mice and the interaction of nanocrystals with biological tissue through biochemical and histological changes of kidney, liver and EAT cells. After intraperitoneal injection of 2.5 × 106 cells into the abdominal cavity of mice, treatment of animals was started next day by injecting RSV or NANO-RSV at a dose of either 25 or 50 mg/kg every other day for 14 days. The results show that the administration of resveratrol and its nanocrystals lead to significant reductions in the proliferation of tumour cells in the abdominal cavity, and a reduction of the number of blood vessels in the peritoneum, with low systemic toxicity. In histopathological examinations, greater hepatocellular necrosis and apoptosis, hepatic fibrosis around the central vein and degeneration with minor fatty change were observed with RSV than with NANO-RSV. Inflammation with proximal tubular necrosis and renal glomerulus swelling were also observed, together with slight elevation of several biochemical parameters in both the RSV and NANO-RSV groups. In order to increase the beneficial effects and reduce risks associated with resveratrol nanocrystals, additional factors such as dose, genetic factors, health status, and the nature of the target cells should also be considered.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Nanoparticles/therapeutic use , Resveratrol/therapeutic use , Abdominal Cavity/pathology , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/toxicity , Antioxidants/pharmacology , Carcinoma, Ehrlich Tumor/drug therapy , Cell Line , Cell Proliferation/drug effects , Humans , Inflammation/chemically induced , Inflammation/pathology , Injections, Intraperitoneal , Male , Mice , Nanoparticles/chemistry , Nanoparticles/toxicity , Particle Size , Peritoneum/blood supply , Regional Blood Flow/drug effects , Resveratrol/chemistry , Resveratrol/toxicity , Xenograft Model Antitumor Assays
19.
Biomolecules ; 11(9)2021 09 16.
Article in English | MEDLINE | ID: mdl-34572583

ABSTRACT

Acute renal failure (ARF) is a clinical critical syndrome with rapid and severe decline of renal function. Complications of ARF, especially its cardiac complications (cardiorenal syndrome type 3, CRS-3), are the main causes of death in patients with ARF. However, the shortage and limited efficacy of therapeutic drugs make it significant to establish new large-scale drug screening models. Based on the Nitroreductase/Metronidazole (NTR/MTZ) cell ablation system, we constructed a Tg(cdh17:Dendra2-NTR) transgenic zebrafish line, which can specifically ablate renal tubular epithelial cells. The absence of renal tubular epithelial cells can lead to ARF in zebrafish larvae. The ARF symptoms, such as heart enlargement, slow heart rate and blood stasis, are similar to the clinical manifestations of human CRS-3. Furthermore, two therapeutic drugs (digoxin and enalapril) commonly used in the clinical treatment of heart failure were also effective in alleviating the symptoms of CRS-3 in zebrafish, which proved the effectiveness of this model. Drug screening further discovered a potential drug candidate, α-lipoic acid, which can effectively alleviate the symptoms of CRS-3 through its antioxidant function. Accordingly, we established a new ARF model of zebrafish, which laid a foundation for large-scale screening of new therapeutic drugs for its complications.


Subject(s)
Acute Kidney Injury/complications , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/etiology , Drug Evaluation, Preclinical , Acute Kidney Injury/pathology , Acute Kidney Injury/physiopathology , Animals , Animals, Genetically Modified , Cardio-Renal Syndrome/drug therapy , Cardio-Renal Syndrome/etiology , Cardiovascular Diseases/pathology , Digoxin/pharmacology , Digoxin/therapeutic use , Disease Models, Animal , Enalapril/pharmacology , Enalapril/therapeutic use , Epithelial Cells/pathology , Humans , Kidney Tubules/pathology , Kidney Tubules/physiopathology , Larva/physiology , Metronidazole , Regional Blood Flow/drug effects , Thioctic Acid/pharmacology , Thioctic Acid/therapeutic use , Treatment Outcome , Zebrafish
SELECTION OF CITATIONS
SEARCH DETAIL